Form 4: Phyllis Yale Reports Acquisition of Bristol-Myers Squibb Deferred Share Units

Director Phyllis Yale reports the acquisition of deferred share units convertible to common stock of Bristol-Myers Squibb.

Summary

• Phyllis Yale, a director of Bristol-Myers Squibb, reported the acquisition of 3,562.341 deferred share units on February 1, 2025.
• These units are convertible into shares of common stock upon settlement, which occurs when Yale ceases to be a director or at a previously specified future date.
• The price of the transaction was $58.95 per unit.
• Following the transaction, Yale beneficially owns 34,677.203 deferred share units, including deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing with no inherent positive or negative sentiment.

Future Outlook

The deferred share units will be converted into common stock upon settlement when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

This filing is a routine disclosure of a director's acquisition of deferred share units, a common form of compensation in publicly traded companies.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects a change in the director's holdings of deferred share units.

Key Dates

Keywords

Form 4, Beneficial Ownership, Deferred Share Units, Director, Bristol-Myers Squibb, BMY, Yale, Phyllis Yale